Literature DB >> 1941962

Genetic counselling in facioscapulohumeral muscular dystrophy.

P W Lunt1, P S Harper.   

Abstract

Clinical data are presented from a survey of 41 families with dominantly inherited facioscapulohumeral muscular dystrophy (FSHD) in which over 500 family members were examined, including 168 affected subjects. New mutation could account for six isolated cases. Results suggest that 33% of heterozygotes over 40 years are mildly affected and a majority develop significant lower limb weakness; 19% over 40 years require wheelchairs. Presymptomatic testing of serum creatine kinase level (CK) is limited as a raised level occurs in only 80% of affected males under 40 years and 48% of affected women. Distribution of weakness, severity, age at onset, and CK varied between subjects, but provided no clinical evidence for genetic heterogeneity in a comparison between the 11 largest families. The conclusion of genetic homogeneity in FSHD, including subjects previously diagnosed as FSH type spinal muscular atrophy, is strongly supported by recent genetic linkage data.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1941962      PMCID: PMC1017051          DOI: 10.1136/jmg.28.10.655

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  22 in total

1.  Formal genetics of muscular dystrophy.

Authors:  N E MORTON; C S CHUNG
Journal:  Am J Hum Genet       Date:  1959-12       Impact factor: 11.025

2.  The myogenic scapulo-peroneal syndrome. Muscular dystrophy in the K. kindred: clinical study and genetics.

Authors:  V M Kazakov; D K Bogorodinsky; A A Skorometz
Journal:  Clin Genet       Date:  1976-07       Impact factor: 4.438

3.  The facio-scapulo-limb (or the facioscapulohumeral) type of muscular dystrophy. Clinical and genetic study of 200 cases.

Authors:  V M Kazakov; D K Bogorodinsky; Z V Znoyko; A A Skorometz
Journal:  Eur Neurol       Date:  1974       Impact factor: 1.710

4.  Genetic-epidemiological studies in progressive muscular dystrophy.

Authors:  J Prot
Journal:  J Med Genet       Date:  1971-03       Impact factor: 6.318

5.  Creatine phosphokinase in facioscapulohumeral muscular dystrophy.

Authors:  B P Hughes
Journal:  Br Med J       Date:  1971-08

6.  Death in childhood due to facio-scapulo-humeral dystrophy.

Authors:  J McGarry; B Garg; S Silbert
Journal:  Acta Neurol Scand       Date:  1983-07       Impact factor: 3.209

7.  Thoracoscapular fusion for facioscapulohumeral dystrophy.

Authors:  S A Copeland; R C Howard
Journal:  J Bone Joint Surg Br       Date:  1978-11

8.  Neurogenic atrophy simulating facioscapulohumeral dystrophy. A dominant form.

Authors:  G M Fenichel; E S Emery; P Hunt
Journal:  Arch Neurol       Date:  1967-09

9.  Chronic spinal muscular atrophy of facioscapulohumeral type.

Authors:  T Furukawa; Y Toyokura
Journal:  J Med Genet       Date:  1976-08       Impact factor: 6.318

10.  Facioscapulohumeral dystrophy presenting in infancy with facial diplegia and sensorineural deafness.

Authors:  B R Korf; M J Bresnan; F Shapiro; A Sotrel; I F Abroms
Journal:  Ann Neurol       Date:  1985-05       Impact factor: 10.422

View more
  31 in total

1.  Facioscapulohumeral dystrophy--an indication for internal fixation of clavicle fractures.

Authors:  M R Sawant; P T Calvert
Journal:  J R Soc Med       Date:  1999-02       Impact factor: 5.344

2.  The Krüppel-like factor 15 as a molecular link between myogenic factors and a chromosome 4q transcriptional enhancer implicated in facioscapulohumeral dystrophy.

Authors:  Petr Dmitriev; Andrei Petrov; Eugenie Ansseau; Luiza Stankevicins; Sébastien Charron; Elena Kim; Tomas Jan Bos; Thomas Robert; Ahmed Turki; Frédérique Coppée; Alexandra Belayew; Vladimir Lazar; Gilles Carnac; Dalila Laoudj; Marc Lipinski; Yegor S Vassetzky
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

3.  Chromatin loop domain organization within the 4q35 locus in facioscapulohumeral dystrophy patients versus normal human myoblasts.

Authors:  Andrei Petrov; Iryna Pirozhkova; Gilles Carnac; Dalila Laoudj; Marc Lipinski; Yegor S Vassetzky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-21       Impact factor: 11.205

4.  Genetic counseling and testing for FSHD (facioscapulohumeral muscular dystrophy) in the Israeli population.

Authors:  Miri Yanoov-Sharav; Esther Leshinsky-Silver; Sarit Cohen; Chana Vinkler; Marina Michelson; Tally Lerman-Sagie; Mira Ginzberg; Menahem Sadeh; Dorit Lev
Journal:  J Genet Couns       Date:  2011-11-23       Impact factor: 2.537

5.  The mapping of chromosome 4q markers in relation to facioscapulohumeral muscular dystrophy (FSHD).

Authors:  M Upadhyaya; P Lunt; M Sarfarazi; W Broadhead; J Farnham; P S Harper
Journal:  Am J Hum Genet       Date:  1992-08       Impact factor: 11.025

6.  Linkage localization of facioscapulohumeral muscular dystrophy (FSHD) in 4q35.

Authors:  K D Mathews; K A Mills; E P Bosch; V V Ionasescu; K R Wiles; K H Buetow; J C Murray
Journal:  Am J Hum Genet       Date:  1992-08       Impact factor: 11.025

7.  A closely linked DNA marker for facioscapulohumeral disease on chromosome 4q.

Authors:  M Upadhyaya; P W Lunt; M Sarfarazi; W Broadhead; J Daniels; M Owen; P S Harper
Journal:  J Med Genet       Date:  1991-10       Impact factor: 6.318

8.  Improved molecular diagnosis of facioscapulohumeral muscular dystrophy (FSHD): validation of the differential double digestion for FSHD.

Authors:  M Upadhyaya; J Maynard; M T Rogers; P W Lunt; P Jardine; D Ravine; P S Harper
Journal:  J Med Genet       Date:  1997-06       Impact factor: 6.318

9.  Facioscapulohumeral dystrophy: case report and discussion.

Authors:  Vincenzo Castellano; Joseph Feinberg; Jennifer Michaels
Journal:  HSS J       Date:  2008-07-01

10.  Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy.

Authors:  Karsten Schepelmann; Yaroslav Winter; Annika E Spottke; Detlef Claus; Christoph Grothe; Rolf Schröder; Dieter Heuss; Stefan Vielhaber; Veit Mylius; Reinhard Kiefer; Bertold Schrank; Wolfgang H Oertel; Richard Dodel
Journal:  J Neurol       Date:  2009-07-24       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.